Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Large-scale testing (Phase 3)Looking for participantsNCT05744687
What this trial is testing

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 374
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Testing effectiveness (Phase 2)Looking for participantsNCT06369285
What this trial is testing

Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc. 225
Not applicableLooking for participantsNCT06587789
What this trial is testing

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

Who this might be right for
Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 286
Large-scale testing (Phase 3)Study completedNCT06009627
What this trial is testing

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 119
Early research (Phase 1)Active Not RecruitingNCT04895761
What this trial is testing

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Who this might be right for
Breast Cancer
Providence Health & Services 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05708235
What this trial is testing

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Who this might be right for
Breast Cancer
MedSIR 976
Large-scale testing (Phase 3)Active Not RecruitingNCT05501886
What this trial is testing

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Who this might be right for
Breast Cancer
Celcuity Inc 701
Testing effectiveness (Phase 2)UnknownNCT05577442
What this trial is testing

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Peking University Cancer Hospital & Institute 52
Very early researchNot Yet RecruitingNCT07446686
What this trial is testing

Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer

Who this might be right for
Breast Cancer
Guizhou Provincial People's Hospital 30
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Very early researchEnded earlyNCT03361800
What this trial is testing

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Who this might be right for
Breast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center 5
Testing effectiveness (Phase 2)Looking for participantsNCT07037199
What this trial is testing

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07745257
What this trial is testing

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

Who this might be right for
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University 40
Not applicableStudy completedNCT05789771
What this trial is testing

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

Who this might be right for
HR+/HER2- Breast CancerMetastatic DiseaseАdvanced Disease
Blokhin's Russian Cancer Research Center 136
Not applicableLooking for participantsNCT07708571
What this trial is testing

Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management

Who this might be right for
HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit 548
Early research (Phase 1)Not Yet RecruitingNCT07163481
What this trial is testing

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Who this might be right for
Stage IV (Metastatic) Breast Cancer
Hunan Cancer Hospital 12
Next Page